The Globe and Mail reports in its Tuesday edition that Melius Research analyst Rob Wertheimer commenced coverage of pot stocks by urging investors to take a "cautious entry" under the belief "the space seems to price in positives that only may come true." The Globe's David Leeder writes that Mr. Wertheimer compares the sector to the tech bubble. He recommends a "basket approach, narrowing as winners are identified." He gave an "overweight" rating to Aurora Cannabis, which is his top pick based on "potential alliances, early scale in production and global reach." He set a $17 target, which exceeds the consensus of $12.50. Mr. Wertheimer gave "neutral" ratings to Canopy Growth and Cronos Group. He targets Canopy at $80, which beats the consensus of $73.37. He targets Cronos at $27, about $9 ahead of the consensus. Mr. Wertheimer says in a note: "The trend toward legalization is broad and becoming unstoppable. Cannabis will affect, then disrupt the beverage industry. Its wide range of potential medicinal uses holds potential to take share in the over-the-counter and pharmaceutical industries over time. ... Canadian cannabis companies have a window ... into other, larger markets as legalization progresses."